Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen [6]

Annals of Internal Medicine

Volumn 137, Issue 2, 2002, Pages 146-147

  Johnson, Stuart ^a   Chan, Juliana ^a   Bennett, Charles L ^a  

^a JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CORTICOSTEROID; NEVIRAPINE;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; EOSINOPHILIA; FEVER; FOLLOW UP; HEALTH CARE PERSONNEL; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; IMMUNOCOMPETENCE; INFECTION PREVENTION; INFECTION RISK; LETTER; LIVER BIOPSY; LIVER NECROSIS; LIVER TOXICITY; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME;

EID: 0037118713     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-137-2-200207160-00025     Document Type: Letter

References (4)

1. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis
2. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP study
3. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection
4. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1